SMA Courses
Adjust font size :   fontsmall   fontbig



<September 2020>

HKU Master of Laws in Medical Ethics and Law Information Session & Lecture on “Legal Responses to Innovations in Medicine”

31 Jan 2020

Course Code:  SMA/January/2020
Time:  12.15pm - 1.45pm
Course Fees:  Complimentary, including members of the public

Academia @ SGH, L2-S3/S4
20 College Rd, Singapore 169856

HKU Master of Laws in Medical Ethics and Law Information Session & Lecture on “Legal Responses to Innovations in Medicine”


Date: 31 January 2020, Friday

Time: 12.15pm - 1.45pm (Registration and Lunch starts at 12pm)

Venue: Academia @ SGH, L2-S3/S4, 20 College Road, Singapore 169856

Speaker: Terry Sheung-Hung KAAN, Associate Professor of the Faculty of Law & Co-Director of the Centre for Medical Ethics & Law, University of Hong Kong

Fee: Complimentary, Members of the public are welcome

Info session: HKU Master of Laws (Medical Ethics and Law)

The Master of Laws in Medical Ethics and Law, or the LLM(MEL), is a ground-breaking cross-disciplinary Masters programme offered by the Faculty of Law of the University of Hong Kong. It addresses concerns of growing importance at the juncture of the healthcare, law and biomedical research professions. It spans important topics such as consent and confidentiality, decisions at the end of life, medical negligence, and the regulation of biomedical research. The information session is intended to give prospective applicants an overview of the programme, and to ask questions about the programme. For more information, please go to

Lecture: "Legal Responses to Innovations in Medicine"
The imminent adoption of precision medicine techniques as a routine tool promises to transform clinical medicine in jurisdictions with advanced healthcare infrastructures, particularly when genomic information is employed in the design, targeting and delivery of precision medicine.  But the routine adoption of precision medicine and genomic medicine also raises some new fundamental issues in common law legal systems (such as that in the UK, Singapore and Hong Kong) that have yet to be resolved.  In particular, what are the legal and ethical responsibilities (and potential liabilities) of clinicians in relation to the large amount of data required by precision medicine and genomic medicine?  In jurisdictions where the private sector plays a significant role in the provision of healthcare services alongside a state-funded universal healthcare system (such as in Hong Kong), the advent of precision medicine is also likely to raise social and ethical issues about equitable access to new technologies.
**This presentation was originally delivered at the Professor Chao Tzee Cheng Visiting Professorship Program Conference 2019 on 6 December 2019 organized by the Department of Pathology, NUS.

For doctors, please include MCR no.

For all other professions and members of the public, please include your profession in the MCR No. field.